Patents by Inventor Isabelle Dussault

Isabelle Dussault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210214446
    Abstract: This disclosure relates to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating biliary tract cancer or inhibiting biliary tract tumor growth in treatment naïve patients, or patients with locally advanced or metastatic BTC who have failed or are intolerant to first-line systemic chemotherapy.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 15, 2021
    Inventors: Motonobu Osada, Samer El Bawab, Isabelle Dussault, Yulia Vugmeyster, Akash Khandelwal, Olaf Christensen, Meng Li
  • Publication number: 20210196822
    Abstract: The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-? inhibition with an anti-TGF? agent, and treating the subject with the anti-TGF? agent.
    Type: Application
    Filed: February 16, 2021
    Publication date: July 1, 2021
    Inventors: George Locke, Isabelle Dussault
  • Publication number: 20210113656
    Abstract: This disclosure relates generally to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating a treatment naïve patient diagnosed with stage III non-small cell lung cancer (NSCLC), and/or mitigating a pathological condition associated with chemotherapy and radiotherapy (cCRT).
    Type: Application
    Filed: December 10, 2020
    Publication date: April 22, 2021
    Inventors: Italia Grenga, Isabelle Dussault, Yulia Vugmeyster, Akash Khandelwal, Olaf Christensen, Samer El Bawab, Yan Lan
  • Publication number: 20210115145
    Abstract: This disclosure relates generally to methods for treating a subject diagnosed with advanced non-small-cell lung cancer (NSCLC), involving targeted TGF-? inhibition with a bi-functional fusion protein, in combination with administration of systemic chemotherapeutic agents, wherein the combination of the bi-functional fusion protein of the present disclosure with systemic chemotherapeutic agents enhances anticancer efficacy over systemic chemotherapeutic agents alone.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Italia Grenga, Isabelle Dussault, Yulia Vugmeyster, Akash Khandelwal, Olaf Christensen
  • Publication number: 20210061899
    Abstract: This disclosure relates to dosage regimens for targeted TGF-? inhibition with a bi-functional fusion protein for use in a method of treating cancer or inhibiting tumor growth in treatment naïve patients.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Inventors: Laureen Ojalvo, Samer El Bawab, Isabelle Dussault, Yulia Vugmeyster, Akash Khandelwal, Olaf Christensen
  • Publication number: 20190330375
    Abstract: This disclosure relates generally to body weight independent (BW-independent) dosing regimens and dosage forms of a bifunctional protein targeting human protein Programmed Death Ligand 1 (PD-L1) and Transforming Growth Factor ? (TGF?).
    Type: Application
    Filed: July 2, 2019
    Publication date: October 31, 2019
    Inventors: Samer El Bawab, Isabelle Dussault, Yulia Vugmeyster, Akash Khandelwal
  • Publication number: 20140243339
    Abstract: This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer, by combining VEGF(R) inhibitors and inhibitors of HGF/SF:c-Met.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicant: Amgen Inc.
    Inventors: Teresa L. Burgess, Angela Coxon, Isabelle Dussault, Paula Kaplan-Lefko, Anthony J. Polverino, Darrin Beaupre
  • Publication number: 20110104161
    Abstract: This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer, by—combining VEGF(R) inhibitors and inhibitors of HGF/SF:c-Met.
    Type: Application
    Filed: May 14, 2009
    Publication date: May 5, 2011
    Inventors: Teresa L. Burgess, Angela Coxon, Isabelle Dussault, Paula Kaplan-Lefko, Anthony J. Polverino, Darrin Beaupre
  • Publication number: 20050037404
    Abstract: The present invention relates to new methods of modifying drug clearance and avoiding multi-drug resistance by modifying SXR activity. SXR is a transcriptional activator of MDR1, cytochrome P40-3A4 and cytochrome P40 2C8. SXR activation can significantly increase the metabolic inactivation and efflux of a wide range of chemotherapeutic agents, for example taxanes. Reducing and/or preventing SXR activation therefore diminishes drug resistance and drug clearance and forms the basis of important therapeutic methods which increase the performance of drugs, such as taxanes. Screening and drug identification methods are described which can identify drugs which are not susceptible to SXR related inactivation and increased efflux. In addition, drugs which can reduce these effects for other agents are provided.
    Type: Application
    Filed: July 13, 2004
    Publication date: February 17, 2005
    Applicant: City of Hope
    Inventors: Timothy Synold, Isabelle Dussault, Barry Forman
  • Publication number: 20050004165
    Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
    Type: Application
    Filed: August 3, 2004
    Publication date: January 6, 2005
    Inventors: Barry Forman, Richard Beard, Isabelle Dussault, Roshantha Chandraratna
  • Publication number: 20040019027
    Abstract: The present invention provides methods for preventing or treating disorders associated with the degradation of cholesterol and bile alcohols through the use of ligands that interact with pregnane X receptors (PXR). In a preferred embodiment, PXR agonists are used to treat disorders associated with sterol 27-hydroxylase (CYP27) deficiency or mutation. The disorders associated with CYP27 deficiency include but not limited to cerebrotendinous xanthomatosis, cataracts, gallstone, tendon xanthomas, atherosclerosis, hepatomegaly, hypertriglyceridemia, and neurological and neuropsychiatric abnormalities such as peripheral neuropathy and dementia. In another preferred embodiment, PXR agonists are used to prevent or treat disorders that can be alleviated by enhancing the degradation of cholesterol or bile alcohols.
    Type: Application
    Filed: April 11, 2003
    Publication date: January 29, 2004
    Inventors: Barry Forman, Isabelle Dussault
  • Publication number: 20030144360
    Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
    Type: Application
    Filed: March 22, 2002
    Publication date: July 31, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Barry M. Forman, Richard L. Beard, Isabelle Dussault, Roshantha A. Chandraratna
  • Publication number: 20020137663
    Abstract: ET-743 is a small molecular weight compound with antineoplastic activity that inhibits the ability of the nuclear receptor SXR to trans activate gene transcription from SXR regulated response elements. The nuclear receptor SXR has been identified as a receptor that activates transcription of the mdr1 gene and thus increases multidrug resistance in cells. The interaction of SXR with the mdr1 gene and ET-743 provide a set of physiological mechanisms which can be exploited to identify novel inhibitors of SXR activation and mdr1 gene transcription and thus novel agents which exhibit an antineoplastic effect against tumor cells either alone or when coadministered with another antineoplastic agent.
    Type: Application
    Filed: August 13, 2001
    Publication date: September 26, 2002
    Inventors: Barry M. Forman, Isabelle Dussault
  • Publication number: 20020061836
    Abstract: The orphan nuclear receptor SXR coordinately regulates drug clearance in response to a wide variety of xenobiotic compounds. The disclosure demonstrates that an HIV protease inhibitor binds SXR and activates its target genes. SXR ligands activate expression of MRP2, a critical regulator of bile flow and biliary drug excretion. Therefore, SXR binding compounds can be used for regulating drug clearance and treatment of hepatic disorders associated with impaired bile flow. The present invention relates to new methods of modifying drug clearance and avoiding multi-drug resistance by modifying SXR activity. SXR is a transcriptional activator of MDR1, cytochrome P40-3A4 and cytochrome P40 2C8. SXR activation can significantly increase the metabolic inactivation and efflux of a wide range of chemotherapeutic agents, for example taxanes.
    Type: Application
    Filed: July 17, 2001
    Publication date: May 23, 2002
    Inventors: Barry Forman, Isabelle Dussault, Timothy W. Synold
  • Publication number: 20020022599
    Abstract: The present invention relates to new methods of modifying drug clearance and avoiding multi-drug resistance by modifying SXR activity. SXR is a transcriptional activator of MDR1, cytochrome P40-3A4 and cytochrome P40 2C8. SXR activation can significantly increase the metabolic inactivation and efflux of a wide range of chemotherapeutic agents, for example taxanes. Reducing and/or preventing SXR activation therefore diminishes drug resistance and drug clearance and forms the basis of important therapeutic methods which increase the performance of drugs, such as taxanes. Screening and drug identification methods are described which can identify drugs which are not susceptible to SXR related inactivation and increased efflux. In addition, drugs which can reduce these effects for other agents are provided.
    Type: Application
    Filed: March 23, 2001
    Publication date: February 21, 2002
    Inventors: Timothy W. Synold, Isabelle Dussault, Barry M. Forman